RxDoctor Payments DataLook up a doctor →

Casey Boyles, MD

Family Medicine · Cedar Rapids, IANPI 1669459921

Payments from drug & device makers

$8,108in general payments, 2019–2025

Across 624 payments — averaging $12.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Pfizer$862
  • Novo Nordisk$684
  • Amgen$500
  • Lilly USA, LLC$277
  • plus $4K from 45 others

What the payments were for

  • Food & beverage$8,00599%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,108 in reported general payments places this provider in the 95th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$168,234
Medicare patients
439
Services billed
2,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin150$178,980
Tresiba Flextouch U-200Insulin Degludec90$95,469
XareltoRivaroxaban67$66,465
EliquisApixaban49$59,846
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$52,939
OzempicSemaglutide37$41,467
FarxigaDapagliflozin Propanediol37$40,209
MounjaroTirzepatide39$37,662
TrulicityDulaglutide33$33,510
Bydureon BciseExenatide Microspheres20$25,400
VraylarCariprazine Hcl16$24,419
JanuviaSitagliptin Phosphate11$17,820
Tresiba Flextouch U-100Insulin Degludec23$12,973
Novolog FlexpenInsulin Aspart21$9,641
Dexlansoprazole DrDexlansoprazole27$9,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$218$178,980150 claims
Lilly USA, LLCMounjaro, Trulicity$277$71,17372 claims
Johnson & JohnsonXarelto$211$66,46567 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$222$66,367112 claims
PfizerEliquis$862$59,84649 claims
Novo NordiskOzempic$684$41,46737 claims
AstraZenecaFarxiga$1,002$40,20937 claims
AbbVieVraylar$1,281$24,41916 claims
MerckJanuvia$65$17,82011 claims
Astellas Pharma US IncMyrbetriq$199$6,49812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →